Lingohr Asset Management GmbH Sells 36,209 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• Lingohr Asset Management GmbH significantly reduced its stake in BioNTech SE by 84.1%, now holding only 6,822 shares, reflecting a valued position of approximately $726,000 in the company.
• Several hedge funds have been active with BioNTech, with Millennium Management LLC increasing its holdings by 252.5%, while GAMMA Investing LLC raised theirs by an astonishing 5,710.8% during recent quarters.
• BioNTech reported a revenue of $306.46 million for the latest quarter, showing a significant increase of 102.6% compared to the same period last year, despite missing EPS estimates.

Lingohr Asset Management GmbH decreased its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 84.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 6,822 shares of the company's stock after selling 36,209 shares during the period. BioNTech comprises approximately 1.3% of Lingohr Asset Management GmbH's portfolio, making the stock its 29th biggest holding. Lingohr Asset Management GmbH's holdings in BioNTech were worth $726,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Tema Etfs LLC bought a new stake in shares of BioNTech in the 4th quarter worth approximately $513,000. USS Investment Management Ltd bought a new stake in shares of BioNTech during the fourth quarter valued at approximately $3,117,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of BioNTech by 19.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 221,080 shares of the company's stock valued at $25,192,000 after purchasing an additional 36,746 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of BioNTech during the 4th quarter valued at $235,000. Finally, Jefferies Financial Group Inc. bought a new stake in shares of BioNTech during the 4th quarter valued at $570,000. Institutional investors own 15.52% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on BNTX. HC Wainwright reissued a "buy" rating and issued a $136.00 price target on shares of BioNTech in a research report on Monday, September 8th. JPMorgan Chase & Co. dropped their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Leerink Partners set a $112.00 target price on shares of BioNTech in a research note on Monday, June 2nd. Morgan Stanley upped their target price on shares of BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Finally, Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Eleven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $134.23.

BioNTech Trading Down 0.1%

NASDAQ BNTX traded down $0.09 during trading hours on Friday, hitting $96.23. 325,317 shares of the company were exchanged, compared to its average volume of 965,302. The stock has a market cap of $23.13 billion, a PE ratio of -60.14 and a beta of 1.39. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average price of $107.68 and a 200 day moving average price of $103.60. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $129.27.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The company had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. Analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.